SCHEMBL15070397

SCHEMBL15070397

Cc1ncc(-c2ccc(NC(=O)c3cscn3)cc2)s1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.43
MAP3K5 Q99683 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GRM1 Q13255 1/20 0.42
DGAT1 O75907 3/20 0.41
ROCK2 O75116 1/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
CSF1R P07333 2/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
CNR1 P21554 1/20 0.39
ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15070508 0.80 RAB9A (0.59) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL17147287 0.76 GRM5 (0.52) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL1249547 0.75 GRM4 (0.58) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL15707225 0.74 MAPT (0.57) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL15707412 0.74 RAB9A (0.47) GRM4MAP3K5NPC1RAB9ASMN1; SMN2
SCHEMBL2430624 0.74 GRM4 (0.56) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL15701090 0.74 GRM4 (0.56) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL168520 0.73 GRM4 (0.63) GRM4PTGDR2NPC1RAB9ASMN1; SMN2
SCHEMBL27530033 0.73 MAPT (0.60) GRM4PTGDR2MAP3K5NPC1RAB9A
SCHEMBL2430811 0.73 MAPT (0.47) GRM4NPC1RAB9ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR GRM4 3193/4885PTGDR2 6/4885MAP3K5 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.